# Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

> **NCT05732831** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tango Therapeutics, Inc.** · enrollment: 225 (estimated)

## Conditions studied

- Locally Advanced Solid Tumor

## Interventions

- **DRUG:** TNG462
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05732831
- **Lead sponsor:** Tango Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-26
- **Primary completion:** 2026-05
- **Final completion:** 2026-09
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732831, "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05732831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*